Fulcrum Therapeutics Continues to Reward Talent with Inducement Grants
In an effort to attract top talent and retain key executives, Fulcrum Therapeutics, a leading biopharmaceutical company specializing in rare genetic diseases, announced the granting of non-statutory stock options to Dr.Patrick Horn, the newly appointed chief medical officer.This move comes as part of the company’s ongoing commitment to incentivize and reward employees for their valuable contributions.
Under the Nasdaq Listing Rule 5635(c)(4), Fulcrum Therapeutics issued stock options to Dr.Horn as an inducement to join the company.This action is in line with the company’s 2022 Inducement Stock Incentive Plan, which aims to attract top talent by offering competitive compensation packages.
This recent announcement follows a similar press release from December 2023, where Fulcrum Therapeutics granted stock options to new employees joining the company.With a total of 61.58 million shares outstanding and a current share price of $9.79, Fulcrum Therapeutics continues to demonstrate its commitment to rewarding employees and fostering a culture of innovation and excellence.
As Fulcrum Therapeutics remains at the forefront of developing life-changing treatments for rare diseases, the company’s inducement grants serve as a testament to its dedication to attracting top talent and driving advancements in the field of biopharmaceuticals.
Comments